Manitoba continues to battle the highest per-capita COVID-19 infection rate in Canada as the country reaches a vaccination milestone, with half the national population having received a first dose.
COVID-19: Canada expects nine million Pfizer doses by end of June nugget.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nugget.ca Daily Mail and Mail on Sunday newspapers.
A homegrown mRNA vaccine for COVID-19 shows promising results in its first small trial and its maker is hoping to test it directly against the vaccine from Pfizer-BioNTech.
Calgary-based Providence Therapeutics says its vaccine produced no serious adverse events and developed good antibodies against COVID-19 that compare favourably with the two mRNA vaccines already on the market from Pfizer and Moderna. We re extremely pleased, said Providence CEO Brad Sorenson.
Get top stories in your inbox.
Our award-winning journalists bring you the news that impacts you, Canada, and the world. Don t miss out.
Email
The Phase 1 trial included 60 healthy adults between 18 and 64, with more than half of them receiving two doses of the vaccine, four weeks apart. The results have not yet been peer-reviewed.
Canadian maker of promising mRNA vaccine looks to test it against Pfizer in new trial
by The Canadian Press
Last Updated May 13, 2021 at 12:28 pm EDT
OTTAWA A homegrown mRNA vaccine for COVID-19 shows promising results in its first small trial and its maker is hoping to test it directly against the vaccine from Pfizer-BioNTech.
Calgary-based Providence Therapeutics says its vaccine produced no serious adverse events and developed good antibodies against COVID-19 that “compare favourably” with the two mRNA vaccines already on the market from Pfizer and Moderna.
The Phase 1 trial included 60 healthy adults between 18 and 64, with more than half of them receiving two doses of the vaccine, four weeks apart. The results have not yet been peer-reviewed.